Citi lowered the firm’s price target on Bio-Techne (TECH) to $70 from $80 and keeps a Neutral rating on the shares. The firm updated models in the life science tools and diagnostics group post the Q4 reports. Coming away from earnings, investor appetite for the sector “remains very light,” primarily due to ongoing U.S. government pressure, the analyst tells investors in a research note. However, Citi sees pockets of the market to be constructive on, such as bioprocessing, where it believes a recovery is underway. Danaher (DHR) is the firm’s top pick.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH:
- Bio-Techne price target lowered to $90 from $95 at Argus
- Bio-Techne expanded menu of RNAscope probes
- Electronic Arts initiated, Workday downgraded: Wall Street’s top analyst calls
- Bio-Techne downgraded to Neutral from Outperform at Baird
- Bio-Techne’s Strong Growth Prospects and Strategic Positioning Drive Buy Rating
Questions or Comments about the article? Write to editor@tipranks.com